Co-Written by: Michael Hogan, Esq.
Pei-Ru Wey, Esq.
R. Touhey Myer, Esq.
The Federal Circuit in HZNP Meds. LLC v. Actavis Labs. UT, Inc., 940 F.3d 680 (Fed. Cir. 2019) reiterated that the term “consisting essentially of” permits inclusion of…Read More
In this recent case in the District of Delaware, the court refused to award either enhanced damages or attorney fees after the jury found willful patent infringement. The Court’s application and analysis of the Read factors, while certainly case-specific, are instructive…Read More
We here continue our discussion of the antitrust fallout after settlement of the recent In re Novartis & Par Antitrust Litigation case, C.A. 18-cv-4361 (AKA), 2019 U.S. Dist. LEXIS 138133, *5 (Aug. 15, 2019). To recap, the case arose from an agreement entered between…Read More
The Southern District of New York’s ruling in In re Novartis & Par Antitrust Litigation provides insight into how to limit the number of claims asserted in a pay for delay antitrust suit; and, more importantly, illustrates…Read More